Skip to main content
梓橦宫 logo

梓橦宫 — Investor Relations & Filings

Ticker · 920566 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 625 across all filing types
Latest filing 2022-07-06 Legal Proceedings Report
Country CN China
Listing Beijing Stock Exchange 920566

About 梓橦宫

http://www.zitonggong.com/

Zitonggong specializes in the research, development, and production of specialized therapeutic agents. Established with a heritage dating back to 1780, the company holds a recognized heritage brand designation. Its primary product portfolio centers on neurological and cerebrovascular health, featuring Oxiracetam in various dosage forms for treating cognitive dysfunction and brain injuries. The company also develops treatments for digestive health, including Compound Aloe Capsules, and produces artificial Oriental Bezoar. Operations are centered on integrating traditional medicinal knowledge with modern chemical synthesis and manufacturing standards. The company maintains a focus on clinical efficacy and technological advancement in the fields of neurology and gastroenterology.

Recent filings

Filing Released Lang Actions
上海天璇律师事务所关于四川梓撞宫药业股份有限公司2022年第二次临时股东大会的法律意见书
Legal Proceedings Report Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the procedural legality of a company's 2022 second extraordinary general meeting (临时股东大会). It details the convening, attendance, voting procedures, and results of the shareholders' meeting. The document does not contain financial statements or management discussion but focuses on the validation of the meeting process and voting results. It is not an announcement of voting results per se, but a legal opinion on the meeting's procedural compliance. Given the nature of the document as a legal opinion on a shareholders' meeting, it fits best under Legal Proceedings Report (LTR) rather than Declaration of Voting Results (DVA) or Regulatory Filings (RNS). The document length is 3153 characters, which is relatively short but contains substantive legal opinion content, not just an announcement or certification. Therefore, the classification is LTR with high confidence.
2022-07-06 Chinese
关于全资子公司完成工商注册登记并取得营业执照的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the completion of business registration and obtaining a business license for a wholly-owned subsidiary of the company. It includes details about the subsidiary's registration, capital, legal representative, and business scope. There is no financial data, report, or detailed analysis presented. The document is a regulatory announcement about corporate structural changes, specifically the establishment of a subsidiary, rather than a financial report or management discussion. Therefore, it fits best under Regulatory Filings (RNS) as a general corporate announcement that does not fit other specific categories.
2022-07-04 Chinese
关于召开2022年第二次临时股东大会的通知公告（提供网络投票）
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice announcing the convening of the 2022 second extraordinary general meeting of shareholders (临时股东大会) for the company 四川梓橦宫药业股份有限公司. It details the meeting date, voting methods, agenda items to be discussed, registration procedures, and contact information. There is no financial data or report content included, only the announcement of the meeting and its logistics. The document length is 2444 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, this document fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2022-06-20 Chinese
对外投资设立全资子公司的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Sichuan Zitonggong Pharmaceutical Co., Ltd. regarding the establishment of a wholly-owned subsidiary for new drug research. It details the investment overview, board approval, and the purpose and risks of the investment. There is no financial data or report content, but rather a corporate action announcement about capital investment and subsidiary formation. This fits the category of Capital/Financing Update (CAP), as it relates to company fundraising or capital structure changes through setting up a new subsidiary with registered capital.
2022-06-20 Chinese
第三届监事会第十次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a meeting resolution announcement from the Supervisory Board (监事会) of the company, detailing the convening, attendance, and voting results of a specific board meeting held on June 20, 2022. It includes information about a proposal to change registered capital and amend the company bylaws, with voting results and procedural compliance statements. The document is short (958 characters) and serves as an official announcement of the meeting's resolutions rather than a full report or detailed financial disclosure. It does not contain financial statements or detailed management discussion, nor is it a shareholder meeting voting result announcement. It fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2022-06-20 Chinese
关于拟修订公司章程的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the proposed amendments to the company's Articles of Association (公司章程), specifically reflecting changes in registered capital and total shares following a rights distribution plan. It references regulatory compliance with company law and stock exchange listing rules, and mentions that the amendments require shareholder approval at a general meeting. The document is relatively short (1041 characters) and serves as a formal notice of the intended changes rather than the full amended Articles or a detailed report. This fits the profile of a Regulatory Filing (RNS) as it is a general regulatory announcement about corporate governance changes and capital structure updates, but not a full report or detailed financial statement. It is not a full Annual Report, Capital/Financing Update, or Share Issue announcement since it mainly focuses on the amendment announcement and related disclosures.
2022-06-20 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.